OMEROS CORP
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
OMER$17.30-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| | Three Months Ended March 31, | |||
|---|---|---|---|---|
| · 2025 · 2024 | ||||
| Operating activities: · · | ||||
| Net loss | $(33,460) | $(37,184) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | |||
| Stock-based compensation expense | 2,453 | 2,658 | ||
| Amortization of non-cash interest and issuance costs on term debt | 325 | — | ||
| Depreciation and amortization | 289 | 204 | ||
| Amortization of discount and issuance costs on convertible notes | 148 | 308 | ||
| Non-cash interest remeasurement on the OMIDRIA royalty obligation | (3,372) | 1,079 | ||
| Non-cash interest on OMIDRIA contract royalty asset | (3,954) | (4,343) | ||
| Remeasurement of OMIDRIA contract royalty asset | (166) | (2,339) | ||
| Accretion on U.S. government treasury bills, net | — | (1,893) | ||
| Changes in operating assets and liabilities: | | |||
| OMIDRIA contract royalty asset | 6,682 | 9,363 | ||
| Receivables | 663 | 454 | ||
| Prepaid expenses and other | (472) | (5,090) | ||
| Accounts payable and accrued expense | (4,977) | (4,997) | ||
| Net cash used in operating activities | (35,841) | (41,780) | ||
| Investing activities: | ||||
| Proceeds from the sale and maturities of investments | 39,300 | 425,687 | ||
| Purchases of investments | (718) | (487,554) | ||
| Purchases of property and equipment | (41) | (58) | ||
| Net cash provided by (used in) investing activities | 38,541 | (61,925) | ||
| Financing activities: | ||||
| Proceeds upon exercise of stock options | 63 | 32 | ||
| Proceeds from sale of future royalties | — | 115,525 | ||
| Principal payments on OMIDRIA royalty obligation | (1,722) | (5,141) | ||
| Payments on finance lease obligations | (180) | (134) | ||
| Repurchases of common stock | — | (11,851) | ||
| Net cash provided by (used in) financing activities | (1,839) | 98,431 | ||
| Net increase (decrease) in cash and cash equivalents | 861 | (5,274) | ||
| Cash and cash equivalents at beginning of period | 3,400 | 7,105 | ||
| Cash and cash equivalents at end of period | $4,261 | $1,831 | ||
| | | | ||
| Supplemental cash flow information | ||||
| Cash paid for interest | $10,218 | $7,152 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.